/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a biopharmaceutical company using our proprietary Precision Timed Release TM ( PTR TM ) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial foc…
$5.24
+$0.09 (+1.75%)
EOD Sep 18, 2026
Negative free cash flow of -$17M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$29M
▼ -35.6% YoY
Op. Margin
—
ROIC
-106.06%
▲ +1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$21M
▲ +6.7% YoY
Op. Cash Flow (TTM)
-$21M
▲ +6.5% YoY
Net Debt
-$22M
Net Cash Position
Cash & Equiv.
$28M
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.